Omeros (NASDAQ:OMER) Raised to Strong-Buy at RODMAN&RENSHAW

Omeros (NASDAQ:OMER) was upgraded by equities researchers at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

A number of other equities research analysts also recently commented on the company. Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday. They issued a “buy” rating and a $9.00 target price on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday. Finally, StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.00.

Omeros Stock Down 2.9 %

Shares of OMER opened at $6.75 on Thursday. Omeros has a 52-week low of $1.38 and a 52-week high of $7.51. The stock has a fifty day simple moving average of $4.08 and a two-hundred day simple moving average of $4.07. The company has a market capitalization of $391.14 million, a PE ratio of -2.92 and a beta of 1.47.

Hedge Funds Weigh In On Omeros

Institutional investors have recently modified their holdings of the business. MML Investors Services LLC boosted its position in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the period. State Street Corp increased its holdings in shares of Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the period. HighTower Advisors LLC lifted its holdings in shares of Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 4,000 shares during the period. Comerica Bank grew its position in Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 6,435 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.